Turcot syndrome clinical trials
The registry lists 60 studies for Turcot syndrome across more than 10 countries. 29 are recruiting or about to start. 13 of them are mainly about Turcot syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Turcot syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Sun Yat-sen University (4) · National Cancer Institute (NCI) (4) · Shanghai Zhongshan Hospital (3) · San Raffaele University (2) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · GlaxoSmithKline (2) · Incyte Corporation (2) · AIO-Studien-gGmbH (1)
What is being tested here
Drugs under test in Turcot syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Toripalimab | 3 | 0 | 3 |
| Pembrolizumab | 2 | 0 | 4 |
| Nivolumab | 1 | 0 | 4 |
| Avelumab | 1 | 0 | 3 |
| Ipilimumab | 1 | 0 | 2 |
| Iparomlimab/Tuvonralimab | 1 | 0 | 1 |
| Anti-CTLA-4 Monoclonal Antibody SHR-8068 | 1 | 0 | 1 |
| Celecoxib | 1 | 0 | 1 |
| Dostarlimab | 1 | 0 | 1 |
| Sintilimab | 1 | 0 | 1 |
Drug classes tested here Immune checkpoint inhibitors 11 open
Coming up
0phase 3 studies under way
5studies finish main data collection within a year
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 5
- Jan 2027MMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastrointestinal Cancers · Shanghai Zhongshan Hospital
- Apr 2027Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin · AIO-Studien-gGmbH
- Apr 2027Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer · Sun Yat-sen University
- Aug 2027Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. · Novartis Pharmaceuticals
- Oct 2027Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Who these studies take
Of the 19 Turcot syndrome studies recruiting now, 16 (84%) set no upper age limit and 2 (11%) stop at 75 or younger. 3 (16%) take children under 18. 2 (11%) are for women only and 1 (5%) for men only; 1 (5%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (16%) | 3 (16%) |
| 18 | 18 (95%) | 16 (84%) |
| 30 | 18 (95%) | 16 (84%) |
| 40 | 18 (95%) | 17 (89%) |
| 50 | 17 (89%) | 17 (89%) |
| 65 | 17 (89%) | 17 (89%) |
| 75 | 17 (89%) | 17 (89%) |
| 85 | 15 (79%) | 15 (79%) |
Across all 60 studies, recruiting or not: 13% stop at 75 or younger and 7% at 65; 12% take children; 10% are for women only and 3% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting1
- ABCSG R07 Rectal Cancer RegistryOct 30, 2026NCT07780305
Results posted1
- Pilot Study of Nivolumab in Pediatric Patients With Hypermutant CancersNov 5, 2026NCT02992964
Studies
Recruiting first, then most recently updated. Showing 50 of 60. Browse all 60 → or search them.
- Prostate Cancer Genetic Risk Evaluation and Screening StudyRecruitingNCT051296051 country
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsRecruitingNCT06305962Early Phase 11 country
- ABCSG R07 Rectal Cancer RegistryRecruitingNCT077803051 country
- EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsRecruitingNCT07262619Phase 1/215 countries
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruitingNCT017931681 country
- MMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastrointestinal CancersNot yet recruitingNCT07625735
- Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI TumorsRecruitingNCT078290811 country
- A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsRecruitingNCT07213609Phase 1/29 countries
- A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC)Not yet recruitingNCT07807800Phase 1/2
- PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial CancerRecruitingNCT06549855Not applicable1 country
- Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch SyndromeNot yet recruitingNCT07360834Not applicable9 countries
- Familial Investigations of Childhood Cancer PredispositionRecruitingNCT030502681 country
- Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal CancerRecruitingNCT06903858Phase 21 country
- Lynch Syndrome X-Talk of Enteral Mucosa With Immune SystemRecruitingNCT067084292 countries
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyRecruitingNCT06362369Phase 1/21 country
- Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease DetectionRecruitingNCT074506121 country
- Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal CancerNot yet recruitingNCT07403877Phase 21 country
- Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair DeficiencyNot yet recruitingNCT07385846Phase 11 country
- Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 StudyNot yet recruitingNCT07266025Phase 2
- Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial CancerNot yet recruitingNCT07369986Phase 2
- Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07259473Phase 2
- Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal CancerRecruitingNCT03926338Phase 21 country
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruitingNCT034527742 countries
- Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.Not yet recruitingNCT06646445Phase 21 country
- SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)RecruitingNCT06278857Phase 21 country
- Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal CancerRecruitingNCT04636008Phase 1/21 country
- Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaRecruitingNCT05729646Phase 21 country
- Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal CancerNot yet recruitingNCT05913570Phase 21 country
- A Phase I/II Study of Regorafenib Plus Avelumab in Solid TumorsRecruitingNCT03475953Phase 1/21 country
- Pilot Study of Nivolumab in Pediatric Patients With Hypermutant CancersTerminatedNCT02992964Phase 1/25 countries
- A Beta-only IL-2 ImmunoTherapY StudyActive, not recruitingNCT05086692Phase 1/28 countries
- Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.Active, not recruitingNCT05838768Phase 115 countries
- Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorActive, not recruitingNCT03607890Phase 21 country
- Liquid Biopsy Biomarkers for Endoscopic Surveillance in Lynch SyndromeCompletedNCT078382461 country
- A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 InactivationActive, not recruitingNCT04104893Phase 21 country
- Neoadjuvant Immunotherapy for T4 dMMR Colon CancerActive, not recruitingNCT06215677Phase 21 country
- Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or MedulloblastomaActive, not recruitingNCT02359565Phase 12 countries
- Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal CancerActive, not recruitingNCT05426005Phase 1/21 country
- Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyWithdrawnNCT04500548Phase 12 countries
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid CancersActive, not recruitingNCT03935893Phase 21 country
- T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid TumorsActive, not recruitingNCT05200559Phase 1/21 country
- Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare)Active, not recruitingNCT074612461 country
- Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)Active, not recruitingNCT03767348Phase 25 countries
- A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsActive, not recruitingNCT06710847Phase 1/27 countries
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 21 country
- Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for OxaliplatinActive, not recruitingNCT05118724Phase 21 country
- Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerActive, not recruitingNCT02983578Phase 21 country
- SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasCompletedNCT03894618Phase 14 countries
- Frequency of Endometrial Cancer Precursors Associated with Lynch SyndromeCompletedNCT052570571 country
- Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsTerminatedNCT05909995Phase 13 countries